Biopharma

Sartorius - Lab Weighing

Cell culture expansion by multiple passaging steps is necessary when going from a stock culture to a Bioreactor for large-scale growth. 
Sartorius introduces the Mycap® CCX cell culture expansion system.
It is designed for aseptic cell culture expansion outside a laminar flow hood with no risk of contamination.
Key Benefits of the System:
- Reduce risk of contamination
- Bypass the biosafety cabinet
- Digital batch records

Cell Passaging With Mycap® CCX and Cubis® II

Creative Bioarray

Flow cytometry data analysis has been considered as the most critical parameter in biological experiments. The major principle of data analysis is to selectively display the cells of interest and to find out more about your cells. This method is referred to as "gating" in flow cytometry, as well as a gate can be defined as a combination of one or more regions. The region is a set of points that are carefully selected by the user, determining an area on the graph.

https://www.creative-bioarray.com/support/data-analysis-in-flow-cytometry.htm

Flow Cytometry

Creative Bioarray dedicates in assisting our customer in cancer drug researches and can offer our customers with readily growing sub-lines that show a clear resistance to the selection agent to accelerate their studies.

https://www.creative-bioarray.com/Services/drug-resistant-cell-model-generation.htm

Drug-Resistant Cell Model Generation

Classical methods to analyze kinase activity involve the quantification of phosphoryl transfer by detecting the production of the phosphorylated product or the changes in the ratio of ATP to ADP. To assist the efforts in kinase drug discovery, Creative Bioarray offers high quality, time efficient and cost effective kinase solution for assay development, high throughput screening (HTS) and selectivity profiling.

https://dda.creative-bioarray.com/kinase-assay.html

Kinase Screening

Creative Enzymes

An enzyme is a biological catalyst and is almost always a protein. It speeds up the rate of a specific chemical reaction in the cell. The enzyme is not destroyed during the reaction and is used over and over. A cell contains thousands of different types of enzyme molecules, each specific to a particular chemical reaction.

 Enzymes play a key role in the metabolic activities of all organisms from human to microbial. The abnormality in metabolism leads to many metabolic disorders.

Studies have shown that many metabolic disorders are resulted from enzyme deficiency. Enzymes also have a wide range of applications in microbial biotechnology and the diagnosis process. They have been widely used in clinical examination as preferred markers in  disease states such as myocardial infarction, jaundice, pancreatitis, cancer, neurodegenerative disorders, etc. They provide insight into the disease process through the ability of diagnosis, prognosis, and assessment of response therapy.
Studies have shown that many metabolic disorders are resulted from enzyme deficiency. Enzymes also have a wide range of applications in microbial biotechnology and the diagnosis process. They have been widely used in clinical examination as preferred markers in  disease states such as myocardial infarction, jaundice, pancreatitis, cancer, neurodegenerative disorders, etc. They provide insight into the disease process through the ability of diagnosis, prognosis, and assessment of response therapy.
https://www.creative-enzymes.com/product/native-microorganism-nacetylneuraminic-acid-aldolase_778.html

Creative Enzymes: Featured  Enzyme  Products  for  Diagnostic  Use

Creative Enzymes uses its expertise in enzyme manufacturing to supply customers enzymes using for life science research and production of medicines, food, alcohol, beer, fruit juice, fabric, paper, leather goods, etc. Our products are used worldwide in academic, commercial, and government laboratories in diverse applications, including basic research, drug discovery, cancer research, infectious disease research, microbiology, and personalized medicine. As a reliable supplier, Creative Enzymes supplies the products of high quality and competitive cost-effectiveness. We cooperate with a large number of satisfied customers in corresponding fields all over the world.  https://www.creative-enzymes.com/

Great Minds Choose Creative Enzymes

Feiyuebio Antibodies - ELISA - Protein

"Professional producer to supply High Quality, Strict Validation Precoated elisa it.
We provide all species elisa kit for life science research use.
Professional service with update protocal, strict QC.
Profeional tech support for enzyme linked immunosorbent assay kit.
Buy good price elisa kit to reach your research target.
Professional Elisa kit supplier to meet your research needs. "

Professional producer to supply High Quality, Strict Validation Precoated elisa it.

Biopharma PEG (Biochempeg)

Antibody–drug conjugate (ADC), comprising a monoclonal antibody, the cytotoxic payload and the linker, has developed rapidly in recent years.
The ADC linker plays a crucial role in ADC development. An ideal linker should be stable in the circulatory system and release the cytotoxic payload specifically in the tumor. 
Find an ideal ADC linker is not easy. PEGs are perfect as a ADC linker, which can enable higher load ADC species. PEGs can create a shield, encapsulating the ADC payload from its microenvironment, increasing solubility and stability. Additional benefits include reduced immunogenicity, improved pharmacokinetics, increased circulation time and decreased toxicity.
Biopharma PEG is your reliable PEG linker provider for your ADC development. Our unparalleled manufacturing expertise has enabled us to focus on PEG derivatives production from milligrams & grams lab scale to GMP large scale. 
We can provide linear and branched, monodispered and polydispersed PEG derivatives with multifunctional groups to meet your needs. Now, we have hundreds of clients worldwide. Visit biochempeg.com for more details.


USE of PEGs to Accelerate the Development of Antibody Drug Conjugates (ADCs)

Oncotarget

Oncotarget published this trending research paper on July 2, 2022 in Volume 13, entitled, "Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation" by researchers from Discovery Chemistry Research and Technology, Eli Lilly and Company, Madrid, Spain; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, New York, NY.

DOI - https://doi.org/10.18632/oncotarget.28249

Correspondence to - María José Lallena - lallena_maria_jose@lilly.com

Abstract

Abemaciclib is an oral, selective cyclin-dependent kinase 4 & 6 inhibitor (CDK4 & 6i), approved for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) as monotherapy for endocrine refractory disease, and with endocrine therapy (ET) for initial treatment and after progression on ET. Abemaciclib has also shown clinical activity in combination with ET in patients with high risk early BC (EBC). Here, we examined the preclinical attributes of abemaciclib and other CDK4 & 6i using biochemical and cell-based assays. In vitro, abemaciclib preferentially inhibited CDK4 kinase activity versus CDK6, resulting in inhibition of cell proliferation in a panel of BC cell lines with higher average potency than palbociclib or ribociclib. Abemaciclib showed activity regardless of HER2 amplification and phosphatidylinositol 3-kinase (PI3KCA) gene mutation status. In human bone marrow progenitor cells, abemaciclib showed lower impact on myeloid maturation than other CDK4 & 6i when tested at unbound concentrations similar to those observed in clinical trials. Continuous abemaciclib treatment provided profound inhibition of cell proliferation, and triggered senescence and apoptosis. These preclinical results support the unique efficacy and safety profile of abemaciclib observed in clinical trials.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28249

Press release - https://www.oncotarget.com/news/pr/oncotarget-continuous-treatment-with-abemaciclib-leads-to-sustained-and-efficient-inhibition-of-breast-cancer-cell-proliferation/

Keywords - abemaciclib, breast cancer, cell lines, CDK4/6, continuous dosing

About Oncotarget

Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Biopharma

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.